- Gilead Sciences (GILD, Financial) and its subsidiary Kite will showcase significant oncology research at ASCO and EHA 2025 meetings.
- Notable presentations include data on Trodelvy® in combination with Keytruda® showing promising results in metastatic triple-negative breast cancer.
- Kite's novel CAR T-cell therapy is being evaluated for hard-to-treat glioblastoma, along with updates on a multiple myeloma treatment developed with Arcellx.
Gilead Sciences, Inc. (GILD) and its subsidiary Kite are set to unveil transformative data spanning various forms of cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) Annual Congress. The presentations will cover a broad range of research from breast cancer to multiple myeloma, as the company seeks to advance its oncology portfolio.
One of the key presentations at ASCO involves the Phase 3 ASCENT-04 study. It reveals that the combination of Trodelvy® with Keytruda® significantly improves progression-free survival for patients with PD-L1+ metastatic triple-negative breast cancer compared to traditional chemotherapy regimens.
Furthermore, Kite, in collaboration with the University of Pennsylvania, will present Phase 1 findings on an investigational CAR T-cell therapy targeting recurrent glioblastoma, a particularly challenging form of brain cancer.
At the EHA meeting, updated results from the Phase 2 iMMagine-1 study will explore anitocabtagene autoleucel (anito-cel) developed for relapsed or refractory multiple myeloma, marking a key milestone in the strategic partnership between Kite and Arcellx.
These developments underscore Gilead's commitment to innovating cancer treatments and improving patient outcomes. The company aims to leverage its diverse oncology portfolio to drive significant advancements in the field.
